NBE Therapeutics AG
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From NBE Therapeutics AG
Pheon Hopes To Stir Up ADC Space With First-In-Class Compound
The UK firm with a presence in Boston has just emerged but Pheon’s CEO Bertrand Damour tells Scrip that big pharma is already showing interest in its next-generation antibody-drug conjugate.
136 Years And Counting: Boehringer Ingelheim Sees Advantage In Private Structure
The family-owned German pharma dates back to 1885 and tries to keep up with its publicly traded peers by not mimicking everything they do, but with a “value by innovation” focus.
Danish Start-Up ADCendo Takes Aim At Novel Cancer Target With Fresh Funds
Emerging Company Profile: Denmark-based start-up ADCendo says it now has enough money to begin developing antibody-drug conjugates aimed at the novel cancer target uPARAP/Endo180 and deliver proof of concept in humans for one or more indications by the end of 2025.
Boehringer Reflects On Resilience Of Older Therapies
The German group is investing heavily in R&D and the continued strong performance of products like Spiriva and Pradaxa is helping to pay for future innovation.
- Drug Discovery Tools
- Large Molecule
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.